Zantac (Ranitidine) NDMA Contamination: Mass Tort Status in 2026
The Zantac mass tort litigation, centered on FDA findings that ranitidine (Zantac) could produce N-nitrosodimethylamine (NDMA), a probable human carcinogen, at levels far exceeding FDA acceptable daily intake limits, has undergone significant legal developments since the FDA's September 2019 public advisory and subsequent April 2020 request for market withdrawal. As of 2026, Zantac litigation involves hundreds of thousands of claimants alleging a range of NDMA-related cancers including bladder, colorectal, esophageal, gastric, kidney, and pancreatic cancers.
The MDL proceedings before Judge Robin Rosenberg in the Southern District of Florida produced a landmark 2022 ruling excluding plaintiffs' general causation expert witnesses, finding that the epidemiological and scientific evidence presented didn't meet the Daubert standard for reliable expert testimony. Consulting mass tort law firm can help evaluate your specific claim. This ruling effectively ended the federal MDL as a viable litigation vehicle for most plaintiffs, triggering a massive shift to state court litigation. Key state courts (particularly California, Illinois, and Delaware) have been more receptive to alternative scientific evidence and causation expert approaches, creating a bifurcated litigation landscape.
State Court Zantac Litigation: The New Battlefield
Following the federal MDL Daubert ruling, plaintiff firms have concentrated Zantac claims in state courts with more favorable evidentiary standards, particularly California (where a different causation standard applies and state tort law provides specific product liability remedies) and Delaware (where major pharmaceutical manufacturers are incorporated). California JCCP proceedings have advanced with different outcomes on causation expert admissibility than the federal MDL. For claimants with strong individual cancer diagnoses and documented Zantac use, state court litigation remains viable and several defendants (including Boehringer Ingelheim and Pfizer) have reached settlements for specific cancer types. Related: Zantac core litigation overview.
How to File a Claim or Get Help
If you believe you qualify based on the eligibility criteria outlined above, the next step is a free consultation with an experienced attorney who handles this case type. Most plaintiff-side attorneys offer no-cost initial evaluations and work on contingency, meaning you pay nothing unless your case results in a recovery. Bring any relevant documentation to your consultation: receipts, medical records, correspondence, or any evidence of the harm you experienced.
To stay current on case developments, claim deadlines, and settlement news, bookmark this page and subscribe to the LawsuitWatch newsletter. We update our coverage as new court filings, settlement announcements, and eligibility changes are made public.
Free Legal Evaluation
Do You Qualify to File a Claim?
Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.
Zantac Cancer Lawsuit: Can You File a Claim in This Case?: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
Is the Zantac lawsuit still active in 2026?
Yes, Zantac litigation remains active in 2026, primarily in state courts following the 2022 federal MDL Daubert ruling that severely limited the federal proceedings. California, Illinois, and Delaware state courts have active Zantac proceedings with thousands of pending cases. Some defendants have reached settlements for specific cancer types while other cases continue to trial.
What cancers qualify for Zantac lawsuits?
Cancers associated with NDMA exposure that have been the basis for Zantac claims include: bladder cancer, colorectal cancer, esophageal cancer, gastric/stomach cancer, kidney cancer, liver cancer, and pancreatic cancer. The strength of the scientific causation evidence varies by cancer type; bladder and colorectal cancers have the most substantial scientific support in Zantac litigation.
Did the 2022 federal MDL ruling kill all Zantac cases?
No, it effectively ended the federal MDL as the primary litigation vehicle. Plaintiffs whose cases were in the MDL could refile in state courts. State courts are not bound by federal Daubert rulings and have applied different standards to causation expert evidence. California courts in particular have allowed causation experts the federal MDL excluded, keeping significant litigation viable.
How do I know if I qualify for a Zantac claim?
Qualifying factors typically require: documented use of ranitidine (prescription or OTC Zantac or generic) for a sufficient period before cancer diagnosis; diagnosis of a qualifying cancer type; and that the cancer diagnosis occurred within a time frame consistent with NDMA exposure. Most Zantac plaintiff firms offer free case evaluations and will review your prescription records and medical history to assess eligibility.
Have any Zantac defendants settled?
Yes, Boehringer Ingelheim reached settlements in 2023 for its Zantac-related claims; Pfizer and other defendants have reached confidential settlements for specific case categories. GSK (formerly GlaxoSmithKline) has fought more cases toward trial rather than settling broadly. The settlement landscape continues to evolve as individual cases proceed and trial outcomes affect settlement negotiations.
Legal Disclaimer
This article is for general informational purposes only and does not constitute legal advice or create an attorney-client relationship. Lawsuit eligibility, settlement amounts, and case status are subject to change as litigation develops. Always consult a licensed attorney in your jurisdiction before making legal decisions. LawsuitWatch is an independent journalism publication and is not a law firm. LawsuitWatch may receive referral compensation from affiliated legal service providers, which does not influence editorial content.